NCT05349643 — "A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT" trial site landscape

Public-registry site landscape for NCT05349643, “A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT”, a Pigmented Villonodular Synovitis study sponsored by AmMax Bio, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT05349643 (registry record)
Study title	A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT
Official title	A Phase 2, Open-Label, Adaptive, Dose-Ranging Study With Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra Articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor
Sponsor	AmMax Bio, Inc.
Condition(s)	Pigmented Villonodular Synovitis; TGCT; Tenosynovial Giant Cell Tumor
Phase	PHASE2
Listed sites	6
Site countries	United States, Australia, Netherlands

Patient-friendly overview of this study: eichor.com/study/NCT05349643.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT05349643 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →